www.fdanews.com/articles/174352-novo-nordisk-in-licenses-rights-to-xomas-xmeta-program-for-diabetes
Novo Nordisk In-Licenses Rights to Xoma’s XMetA Program for Diabetes
December 7, 2015
Denmark-based Novo Nordisk has in-licensed global development and commercialization rights to Xoma’s XMetA program for diabetes.
Novo Nordisk will pay Xoma $5 million up front and up to $290 million in potential milestone payments. Xoma, meanwhile, will retain commercialization rights for rare disease indications.
Xoma’s allosteric modulating monoclonal antibodies bind to the insulin receptor and have glucoregulatory activity. They also reduce hypoglycemia and weight gain in preclinical models.